Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
Liaw B, Seng S, Galsky M, Tsao C, Febbo P, Oh W. Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer. Journal Of Clinical Oncology 2014, 32: 170-170. DOI: 10.1200/jco.2014.32.4_suppl.170.Peer-Reviewed Original ResearchMetastatic castrate-resistant prostate cancerProstate-specific antigenCastrate-resistant prostate cancerOverall survivalProstate cancerPredictive biomarkersMedian time to PSA progressionTime to PSA progressionSerum prostate-specific antigenLesions prior to treatmentDevelopment of predictive biomarkersDays 1 to 5Drug-related gradeMetastatic tumor biopsiesOral platinum analogueGleason score 8Biomarker developmentImage-guided biopsyImproved overall survivalPre-treatment biopsiesLong natural historyMetastatic tissue samplesPeripheral blood samplesAnti-tumor activityMCRPC patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply